Determinants of cyclophilin A-dependent TRIM5α restriction against HIV-1

Virology

Volumn 379, Issue 2, 2008, Pages 335-341

  Lin, Tsai Yu ^a,b   Emerman, Michael ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cyclophilin; HIV 1; Host defense; Restriction factor; SIV; TRIM5

Indexed keywords

CYCLOPHILIN A; TRIPARTITE MOTIF PROTEIN 5;

ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN RESTRICTION; REVERSE TRANSCRIPTION;

ANIMALS; BASE SEQUENCE; BINDING SITES; CAPSID PROTEINS; CELL LINE; CERCOPITHECUS AETHIOPS; CYCLOPHILIN A; DNA PRIMERS; DNA, VIRAL; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MACACA MULATTA; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES SPECIFICITY; VIRUS INTERNALIZATION;

CERCOPITHECIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 50349098824     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.06.037     Document Type: Article

References (42)

1. Anderson J.L., Campbell E.M., Wu X., Vandegraaff N., Engelman A., and Hope T.J. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J. Virol. 80 19 (2006) 9754-9760
2. Berthoux L., Sebastian S., Sokolskaja E., and Luban J. Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc. Natl. Acad. Sci. U. S. A. 102 41 (2005) 14849-14853
3. Bieniasz P.D. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5 11 (2004) 1109-1115
4. Braaten D., Franke E.K., and Luban J. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J. Virol. 70 6 (1996) 3551-3560
5. Braaten D., Franke E.K., and Luban J. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J. Virol. 70 7 (1996) 4220-4227
6. Bukovsky A.A., Weimann A., Accola M.A., and Gottlinger H.G. Transfer of the HIV-1 cyclophilin-binding site to simian immunodeficiency virus from Macaca mulatta can confer both cyclosporin sensitivity and cyclosporin dependence. Proc. Natl. Acad. Sci. U. S. A. 94 20 (1997) 10943-10948
7. Butler S.L., Hansen M.S., and Bushman F.D. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7 5 (2001) 631-634
8. Chackerian B., Haigwood N.L., and Overbaugh J. Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology 213 2 (1995) 386-394
9. Diaz-Griffero F., Vandegraaff N., Li Y., McGee-Estrada K., Stremlau M., Welikala S., Si Z., Engelman A., and Sodroski J. Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. Virology 351 2 (2006) 404-419
10. Dodding M.P., Bock M., Yap M.W., and Stoye J.P. Capsid processing requirements for abrogation of Fv1 and Ref1 restriction. J. Virol. 79 16 (2005) 10571-10577
11. Franke E.K., and Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 222 1 (1996) 279-282
12. Franke E.K., Yuan H.E., and Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372 6504 (1994) 359-362
13. Gamble T.R., Vajdos F.F., Yoo S., Worthylake D.K., Houseweart M., Sundquist W.I., and Hill C.P. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87 7 (1996) 1285-1294
14. Gitti R.K., Lee B.M., Walker J., Summers M.F., Yoo S., and Sundquist W.I. Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science 273 5272 (1996) 231-235
15. Hatziioannou T., Cowan S., Von Schwedler U.K., Sundquist W.I., and Bieniasz P.D. Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J. Virol. 78 11 (2004) 6005-6012
16. Hatziioannou T., Perez-Caballero D., Cowan S., and Bieniasz P.D. Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J. Virol. 79 1 (2005) 176-183
17. Javanbakht H., Diaz-Griffero F., Stremlau M., Si Z., and Sodroski J. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. J. Biol. Chem. 280 29 (2005) 26933-26940
18. Kaiser S.M., Malik H.S., and Emerman M. Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein. Science 316 5832 (2007) 1756-1758
19. Keckesova Z., Ylinen L.M., and Towers G.J. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J. Virol. 80 10 (2006) 4683-4690
20. Lin T.Y., and Emerman M. Cyclophilin A interacts with diverse lentiviral capsids. Retrovirology 3 (2006) 70
21. Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., and Goff S.P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73 6 (1993) 1067-1078
22. Newman R.M., and Johnson W.E. A brief history of TRIM5alpha. AIDS Rev. 9 2 (2007) 114-125
23. O'Doherty U., Swiggard W.J., and Malim M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74 21 (2000) 10074-10080
24. Owens C.M., Song B., Perron M.J., Yang P.C., Stremlau M., and Sodroski J. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J. Virol. 78 10 (2004) 5423-5437
25. Perez-Caballero D., Hatziioannou T., Yang A., Cowan S., and Bieniasz P.D. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J. Virol. 79 14 (2005) 8969-8978
26. Perez-Caballero D., Hatziioannou T., Zhang F., Cowan S., and Bieniasz P.D. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J. Virol. 79 24 (2005) 15567-15572
27. Sebastian S., and Luban J. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2 (2005) 40
28. Soares M.A., Robertson D.L., Hui H., Allan J.S., Shaw G.M., and Hahn B.H. A full-length and replication-competent proviral clone of SIVAGM from tantalus monkeys. Virology 228 2 (1997) 394-399
29. Sokolskaja E., Berthoux L., and Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J. Virol. 80 6 (2006) 2855-2862
30. Sokolskaja E., Sayah D.M., and Luban J. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J. Virol. 78 23 (2004) 12800-12808
31. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., and Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427 6977 (2004) 848-853
32. Stremlau M., Perron M., Lee M., Li Y., Song B., Javanbakht H., Diaz-Griffero F., Anderson D.J., Sundquist W.I., and Sodroski J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U. S. A. 103 14 (2006) 5514-5519
33. Stremlau M., Song B., Javanbakht H., Perron M., and Sodroski J. Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology 351 1 (2006) 112-120
34. Takeuchi H., Buckler-White A., Goila-Gaur R., Miyagi E., Khan M.A., Opi S., Kao S., Sokolskaja E., Pertel T., Luban J., and Strebel K. Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. J. Virol. 81 15 (2007) 8080-8090
35. Tang C., Ndassa Y., and Summers M.F. Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat. Struct. Biol. 9 7 (2002) 537-543
36. Thali M., Bukovsky A., Kondo E., Rosenwirth B., Walsh C.T., Sodroski J., and Gottlinger H.G. Functional association of cyclophilin A with HIV-1 virions. Nature 372 6504 (1994) 363-365
37. Towers G.J. Control of viral infectivity by tripartite motif proteins. Hum. Gene Ther. 16 10 (2005) 1125-1132
38. Towers G.J., Hatziioannou T., Cowan S., Goff S.P., Luban J., and Bieniasz P.D. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9 9 (2003) 1138-1143
39. Wu X., Anderson J.L., Campbell E.M., Joseph A.M., and Hope T.J. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. U. S. A. 103 19 (2006) 7465-7470
40. Yamashita M., and Emerman M. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J. Virol. 78 11 (2004) 5670-5678
41. Ylinen L.M., Keckesova Z., Wilson S.J., Ranasinghe S., and Towers G.J. Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J. Virol. 79 18 (2005) 11580-11587
42. Zhang F., Hatziioannou T., Perez-Caballero D., Derse D., and Bieniasz P.D. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353 2 (2006) 396-409